SCHEMBL18656873

SCHEMBL18656873

O=C1CC(=O)N(CC(F)c2ccc(Cl)c(Cl)c2)C(=O)N1CCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ SIGMAR1 Q99720 13/20 0.42
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ TMEM97 Q5BJF2 1/20 0.39
▸ DAO P14920 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ HSP90B1 P14625 1/20 0.36
▸ TRAP1 Q12931 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18656953 0.89 PTGS1 (0.40) KMT2AMAPTMEN1USP2GAA
SCHEMBL10159127 0.89 PTGS1 (0.40) KMT2AMAPTMEN1USP2GAA
SCHEMBL10159165 0.89 PTGS1 (0.40) KMT2AMAPTMEN1USP2GAA
SCHEMBL10159253 0.89 PTGS1 (0.40) KMT2AMAPTMEN1USP2GAA
SCHEMBL18656913 0.83 KMT2A (0.51) KMT2AMAPTMEN1USP2GAA
SCHEMBL18250133 0.82 PTGS1 (0.38) KMT2AL3MBTL1ALDH1A1PKM
SCHEMBL18250129 0.82 PTGS1 (0.38) KMT2AL3MBTL1ALDH1A1PKM
SCHEMBL18250126 0.82 PTGS1 (0.38) KMT2AL3MBTL1ALDH1A1PKM
SCHEMBL18656955 0.77 MAPT (0.50) KMT2AMAPTMEN1USP2GAA
SCHEMBL18656967 0.76 MAPT (0.49) KMT2AMAPTMEN1USP2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3144299-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Cambria Pharmaceuticals, Inc. (US) 2017-03-22 — — EP disclosed
Send feedback